• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴雷特食管相关肿瘤射频消融术后疼痛和吞咽困难的病程

The course of pain and dysphagia after radiofrequency ablation for Barrett's esophagus-related neoplasia.

作者信息

Overwater Anouk, Elias Sjoerd G, Schoon Erik J, Bergman Jacques J G H M, Pouw Roos E, Weusten Bas L A M

机构信息

Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands.

Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

出版信息

Endoscopy. 2023 Mar;55(3):255-260. doi: 10.1055/a-1929-1448. Epub 2022 Sep 7.

DOI:10.1055/a-1929-1448
PMID:36070753
Abstract

BACKGROUND

Radiofrequency ablation (RFA) is effective for eradication of Barrett's esophagus (BE) neoplasia, but little is known on the course of pain and dysphagia after RFA. We aimed to describe the course of post-RFA symptoms and to identify possible associated risk factors.

METHODS

In this multicenter, observational cohort study, all RFA procedures registered in a prospective database were included. Patient and treatment characteristics were collected from medical records and patients self-registered post-procedural symptoms in electronic symptom diaries for 14 days. Mixed model regression was used for the analyses.

RESULTS

In total, 255 diaries were completed. Post-RFA pain was reported for 95 % (95 %CI 93-98) of procedures (median duration 14 days; 25th-75th percentiles [p25-p75] 11-14) and major pain for 64 % (95 %CI 58-69; median duration 8 days, p25-p75 3-13). Post-procedural pain significantly increased with BE length, younger age, and no prior ablation. Dysphagia was present after 83 % (95 %CI 79-88) of procedures (median duration 13 days, p25-p75 9-14). The risk of dysphagia decreased with age and increased when patients experienced more pain.

CONCLUSIONS

RFA treatment for BE-related neoplasia seems a significant burden for patients, and post-procedural symptoms should be taken into account when counseling patients before starting endoscopic eradication therapy.

摘要

背景

射频消融术(RFA)对根除巴雷特食管(BE)肿瘤有效,但关于RFA术后疼痛和吞咽困难的病程了解甚少。我们旨在描述RFA术后症状的病程,并确定可能的相关危险因素。

方法

在这项多中心观察性队列研究中,纳入了前瞻性数据库中登记的所有RFA手术。从医疗记录中收集患者和治疗特征,并让患者在电子症状日记中自行记录术后14天的症状。采用混合模型回归进行分析。

结果

共完成255份日记。95%(95%置信区间93 - 98)的手术报告了RFA术后疼痛(中位持续时间14天;第25 - 75百分位数[p25 - p75]为11 - 14),64%(95%置信区间58 - 69;中位持续时间8天,p25 - p75为3 - 13)报告了重度疼痛。术后疼痛随BE长度增加、年龄较小以及未进行过先前消融而显著增加。83%(95%置信区间79 - 88)的手术出现吞咽困难(中位持续时间13天,p25 - p75为9 - 14)。吞咽困难的风险随年龄降低,且在患者疼痛更严重时增加。

结论

RFA治疗BE相关肿瘤对患者似乎是一个重大负担,在开始内镜根除治疗前咨询患者时应考虑术后症状。

相似文献

1
The course of pain and dysphagia after radiofrequency ablation for Barrett's esophagus-related neoplasia.巴雷特食管相关肿瘤射频消融术后疼痛和吞咽困难的病程
Endoscopy. 2023 Mar;55(3):255-260. doi: 10.1055/a-1929-1448. Epub 2022 Sep 7.
2
Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study.预测早期肿瘤性 Barrett 食管行环形射频消融术初始治疗反应的因素:一项前瞻性多中心研究。
Endoscopy. 2013 Jul;45(7):516-25. doi: 10.1055/s-0032-1326423. Epub 2013 Apr 11.
3
Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia.射频消融联合内镜切除治疗 Barrett 食管伴早期肿瘤的疗效。
Clin Gastroenterol Hepatol. 2010 Jan;8(1):23-9. doi: 10.1016/j.cgh.2009.07.003. Epub 2009 Aug 11.
4
Predictive factors of radiofrequency ablation failure in the treatment of dysplastic Barrett's esophagus.发育异常的巴雷特食管治疗中射频消融失败的预测因素。
Clin Res Hepatol Gastroenterol. 2023 Jan;47(1):102065. doi: 10.1016/j.clinre.2022.102065. Epub 2022 Dec 6.
5
Radiofrequency ablation and endoscopic resection in a single session for Barrett's esophagus containing early neoplasia: a feasibility study.单一切除术治疗 Barrett 食管伴早期肿瘤:射频消融与内镜切除术的可行性研究。
Endoscopy. 2012 Dec;44(12):1096-104. doi: 10.1055/s-0032-1325731. Epub 2012 Oct 29.
6
Focal cryoballoon versus radiofrequency ablation of dysplastic Barrett's esophagus: impact on treatment response and postprocedural pain.局灶冷冻球囊与射频消融治疗异型性 Barrett 食管:对治疗反应和术后疼痛的影响。
Gastrointest Endosc. 2018 Nov;88(5):795-803.e2. doi: 10.1016/j.gie.2018.06.015. Epub 2018 Jun 19.
7
The safety and efficacy of radiofrequency ablation following endoscopic submucosal dissection for Barrett's neoplasia.内镜黏膜下剥离术后射频消融治疗Barrett肿瘤的安全性和有效性。
Dis Esophagus. 2018 Mar 1;31(3). doi: 10.1093/dote/dox133.
8
Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus.内镜黏膜下剥离术联合射频消融治疗肿瘤性 Barrett 食管。
Endoscopy. 2012 Dec;44(12):1105-13. doi: 10.1055/s-0032-1310155. Epub 2012 Sep 11.
9
Liquid Nitrogen Spray Cryotherapy is Associated With Less Postprocedural Pain Than Radiofrequency Ablation in Barrett's Esophagus: A Multicenter Prospective Study.液氮喷雾冷冻疗法与射频消融相比,在 Barrett 食管中的术后疼痛更少:一项多中心前瞻性研究。
J Clin Gastroenterol. 2019 Feb;53(2):e84-e90. doi: 10.1097/MCG.0000000000000999.
10
Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus.内镜下黏膜切除术治疗 Barrett 食管黏膜肿瘤。
Curr Opin Gastroenterol. 2013 Jul;29(4):446-53. doi: 10.1097/MOG.0b013e3283622848.

引用本文的文献

1
Efficacy and Safety of Cryoablation in Barrett's Esophagus and Comparison with Radiofrequency Ablation: A Meta-Analysis.冷冻消融术治疗巴雷特食管的疗效与安全性及其与射频消融术的比较:一项荟萃分析
Cancers (Basel). 2024 Aug 23;16(17):2937. doi: 10.3390/cancers16172937.
2
AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.AGA 临床实践指南: Barrett 食管及相关肿瘤的内镜消除治疗。
Gastroenterology. 2024 Jun;166(6):1020-1055. doi: 10.1053/j.gastro.2024.03.019.
3
Hybrid Argon Plasma Coagulation for Barrett's Esophagus and for Colonic Mucosal Resection-A Systematic Review and Meta-Analysis.
混合氩等离子体凝固术用于巴雷特食管和结肠黏膜切除术——一项系统评价与Meta分析
Biomedicines. 2023 Apr 10;11(4):1139. doi: 10.3390/biomedicines11041139.